Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,346 | 2,508 | 29.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Hansa Biopharma AB: Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | 114 | GlobeNewswire (Europe) | Lund, Sweden, June 25, 2025. Hansa Biopharma AB (publ), "Hansa" (Nasdaq Stockholm: HNSA), has today on June 25, 2025 held its Annual General Meeting. The Annual General Meeting was held by physical... ► Artikel lesen | |
HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
11.06. | Hansa Biopharma AB: Hansa Biopharma to attend BIO International Convention | 222 | PR Newswire | LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International... ► Artikel lesen | |
09.06. | Hansa Biopharma AB: Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025 | 257 | PR Newswire | LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS)... ► Artikel lesen | |
27.05. | Hansa Biopharma Plans Restructuring | 2 | Contract Pharma | ||
26.05. | Hansa Biopharma AB: Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency | 200 | GlobeNewswire (Europe) | Lund, Sweden, 26 May 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that it plans to restructure the organization to optimize resource allocation and improve operational... ► Artikel lesen | |
26.05. | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | 1 | Cision News | ||
14.05. | Hansa Biopharma AB: Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS | 300 | PR Newswire | LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first... ► Artikel lesen | |
13.05. | Hansa Biopharma Taps Maria Törnsén as COO and President U.S. | 2 | Contract Pharma | ||
13.05. | Hansa Biopharma AB: Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. | 263 | PR Newswire | LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President... ► Artikel lesen | |
24.04. | Hansa Biopharma Q1 2025 slides: 39% sales growth amid expanding EU commercialization | 3 | Investing.com | ||
24.04. | Hansa Biopharma Appoints New CEO | 1 | Contract Pharma | ||
24.04. | Hansa Biopharma reports Q1 results | 3 | Seeking Alpha | ||
24.04. | Hansa Biopharma AB: Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results | 281 | PR Newswire | Strong product sales and key progress in pipeline catalysts
LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today... ► Artikel lesen | |
24.04. | Hansa Biopharma AB: Hansa Biopharma appoints new Chief Executive Officer | 168 | GlobeNewswire (Europe) | Lund, Sweden, 24 April 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren... ► Artikel lesen | |
03.04. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q1 2025 interim results conference call | 4 | Cision News | ||
25.03. | HANSA BIOPHARMA AB: Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference | 3 | Cision News | ||
21.03. | Hansa Biopharma AB: Hansa Biopharma publishes 2024 Annual and Sustainability Reports | 323 | PR Newswire | LUND, Sweden, March 21, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.
Peter... ► Artikel lesen | |
11.03. | Hansa Biopharma AB: Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients | 292 | PR Newswire | LUND, Sweden, March 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization... ► Artikel lesen | |
04.03. | HANSA BIOPHARMA AB: Hansa Biopharma to attend Leerink Partners Global Healthcare Conference | 1 | Cision News | ||
24.02. | HANSA BIOPHARMA AB: Hansa Biopharma to attend TD Cowen Healthcare Conference | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
MEDIGENE | 0,125 | -10,71 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
MODERNA | 23,305 | +0,17 % | Moderna Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
HEIDELBERG PHARMA | 4,900 | +1,03 % | Vorstands-Interview Exklusiv: Heidelberg Pharma - "Unsere innovative Krebstherapie ist angetreten, um Resistenzen zu überwinden" | Heidelberg Pharma hat sich mit einer klaren Mission dem Kampf gegen Krebs verschrieben: Therapien zu entwickeln, die wirksam, verträglich und vor allem eins können - Resistenzen überwinden. Mit einem... ► Artikel lesen | |
4SC | 0,648 | -0,31 % | PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten | DJ PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Resminostat (Kinselby) negative Empfehlung... ► Artikel lesen | |
CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
VIVORYON THERAPEUTICS | 1,462 | -1,08 % | Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences | Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Halle (Saale) / Munich, Germany, June 27, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen |